Health
Synairgen’s SNG001 advances into phase 3 COVID-19 trial – PMLiVE
UK biotech had initially been testing drug for COPD and asthma
Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing.
SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls the body’s antiviral response.
Initially, Synairgen had been evaluating the drug as a treatment for COPD and asthma, although its focus has now shifted to investigating…
-
General18 hours agoByford rail extension opening marks final stage of Perth Metronet
-
Noosa News24 hours agoFatal traffic crash, Baringa – Sunshine Coast
-
General20 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery
-
Business22 hours agoWhat $10,000 invested in the iShares S&P 500 IVV ETF could be in 10 years